Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 966-973

  Pullarkat, Vinod ^a   Sehgal, Arjun ^a   Li, Liang ^a   Meng, Zhuo ^b   Lin, Allen ^a   Forman, Stephen ^a   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Deferasirox; Hematopoiesis; Iron chelators; Myelodysplastic syndrome; Progenitors; Reactive oxygen species

Indexed keywords

DEFERASIROX; GRANULOCYTE COLONY STIMULATING FACTOR; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT DURATION; UMBILICAL CORD BLOOD;

AGED; AGED, 80 AND OVER; BENZOIC ACIDS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; FEMALE; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REACTIVE OXYGEN SPECIES; TRIAZOLES; UP-REGULATION;

EID: 84862529448     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.018     Document Type: Article

References (23)

1. Gatterman N., Finelli C., Porta M.D., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34:1143-1150.
2. List A.F., Baer M.R., Steensma D., et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008, 112:634a.
3. Malcovati L., Della Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
4. Sanz G., Nomdedeu B., Such E., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112:640a.
5. Leitch H.A., Leger C.S., Goodman T.A., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2:205-211.
6. Greenberg P.L., Koller C.A., Cabantchik Z.I., et al. Prospective assessment of effects of iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010, 34:1560-1565.
7. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114:5251-5255.
8. Gatterman N., Rachmilewitz E.A. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2010, 90:1-10.
9. Oliva E.N., Ronco F., Marino A., Alati C., Pratico G., Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010, 50:1568-1570.
10. Gatterman N., Finelli C., Della Porta M., et al. Hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox: an EPIC post hoc analysis using international Working Group (IWG) 2006 criteria. Blood 2010, 116:2912a.
11. Abdel-Wahab O., Levine R.L. Metabolism and the leukemic stem cell. J Exp Med 2010, 207:677-680.
12. Callens C., Coulon S., Naudin J., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
13. Owusu-Ansah E., Banerjee U. Reactive oxygen species prime Drosiphila hematopoietic progenitors for differentiation. Nature 2009, 461:537-542.
14. Ito K., Hirao A., Arai F., et al. Regulation of oxidative stress by ATM is required for self-renewal of hematopoietic stem cells. Nature 2004, 431:997-1002.
15. Tothova Z., Kollipara R., Huntly B.J., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
16. Ghoti H., Amer J., Winder A., Rachmilewitz E., Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007, 79:463-467.
17. Ghoti H., Fibach E., Merkel D., Perez-Avraham G., Grisariu S., Rachmilewitz E. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron overloaded patients with myelodysplastic syndromes. Haematologica 2010, 95:1433-1434.
18. Chaston T.B., Watts R.N., Yuan J., Richardson D.R. Potent antitumor activity of novel iron chelators derived from Di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation. Clin Cancer Res 2004, 10:7365-7374.
19. Zhao M., Xie F., Li Y., et al. Increased intracellular concentration of reactive oxygen species mediated the deficient hematopoiesis of iron overloaded bone marrow. Blood 2010, 116:4247a.
20. Hur W., Gray N.S. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol 2010, 15:1-12.
21. Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention. Carcinogenesis 2010, 31:90-99.
22. Naka K., Muraguchi T., Hoshii T., Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008, 10:1883-1894.
23. Li L., Li M., Sun C.-L., et al. Altered hematopoietic cell gene expression identifies patients at risk for development of therapy-related leukemia (t-MDS/AML). Blood 2010, 116:234a.